Amarin’s hopes of expanding the label for its omega-3 pill look even bleaker as the FDA has denied the company’s appeal to reconsider its clinical data, sending shares down another 25% in premarket trading Tuesday.

…read more

Source: Amarin tanks as the FDA sticks to its guns on Vascepa


0 No comments